Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by gudisgoodon Apr 12, 2022 3:03am
87 Views
Post# 34595964

RE:RE:Isn’t this down another 50% since September report?

RE:RE:Isn’t this down another 50% since September report?
wofats wrote: Isn't this in play this quarter?  If yes it is another 12M loss on this investment quarter on quarter.

As well
On the 40M ebida are not we at 56M now? Setting the bar fairly low perhaps.


Do you mean the current quarter or Q1? I guess it's in play for both but the Q1 unrealized loss will be around $7M (since it closed Q1 at $6.31) as per the annual report:

"On May 26, 2021 Singular Genomics Systems, Inc. (“SGS”), an investment held within Domain Associated LLC (“Domain”), announced the closing of its initial public offering at a public offering price of USD 22 per share. The Company recorded an unrealized gain of $10,962 [USD 9,100] during the year ended December 31, 2021 and a life to date unrealized gain of $13,772 [USD 11,215] in connection with SGS. As at March 21, 2022, SGS’s share price closed at USD 6.34. Should the share price of SGS remain at this level, the Company would record an unrealized loss of approximately $7,050 [USD 5,599]."

It's come down 15% since then so yes, more unrealized losses to come from this unless something changes before the end of the quarter.
<< Previous
Bullboard Posts
Next >>